Job cuts employee layoffs firings or downsizing Scissors dividing individuals positioned on colorful blocks
Biotech

Agios shedding 100 R&D roles ahead of hoped-for SCD approval

Agios has been shrinking its R&D headcount throughout 2026 as the commercial-stage company looks to shed more than 100 roles by year-end.
James Waldron Nov 5, 2026 8:40am
The cost of waiting What reaching clinical proof-of-concept sooner means for biotech cash burn

The cost of waiting: how early proof-of-concept shapes cash burn

Brought to you by Altasciences
Pipette dripping water droplet with money symbol on it into test tube

T-Therapeutics raises $133M series B with Big Pharma backers

Nov 5, 2026 4:00am
glue glue tips

Evommune’s $1B deal to join Novartis in molecular glue niche

Nov 5, 2026 4:53am
Stock market IPO share price

Rezera revs up for $181M IPO to fund NLRP3 inhibitor ph. 3 trial

Nov 5, 2026 10:15am
obesity overweight weight loss weigh

MetaVia’s GLP-1 sheds liver fat and body weight in phase 1

Nov 5, 2026 9:52am
More News
Fierce Pharma

AZ’s reported $10B offer for Rhythm fuels talks of a bidding war

Nov 5, 2026 9:36am

Cash-strapped Vivoryon regains China rights to kidney prospect

Nov 5, 2026 8:28am

Fierce Biotech Fundraising Tracker '26: Alethio's $90M & more

Nov 5, 2026 6:30am

Fierce Biotech Layoff Tracker 2026: Agios, Ultragenyx & more

Nov 5, 2026 4:00am